The estimated Net Worth of Michael Aaron Kelly is at least $395 Thousand dollars as of 10 August 2024. Mr. Kelly owns over 11,336 units of Hookipa Pharma Inc stock worth over $167,666 and over the last 6 years he sold HOOK stock worth over $0. In addition, he makes $227,506 as Independent Director at Hookipa Pharma Inc.
Michael has made over 1 trades of the Hookipa Pharma Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently he exercised 11,336 units of HOOK stock worth $59,854 on 10 August 2024.
The largest trade he's ever made was exercising 11,336 units of Hookipa Pharma Inc stock on 10 August 2024 worth over $59,854. On average, Michael trades about 493 units every 0 days since 2019. As of 10 August 2024 he still owns at least 31,755 units of Hookipa Pharma Inc stock.
You can see the complete history of Mr. Kelly stock trades at the bottom of the page.
Michael A. Kelly serves as Independent Director of the Company. Mr. Kelly is currently the President of Sentry Hill Partners, LLC, a consulting firm in the global life sciences industry that he founded in 2018. He previously served in various leadership positions at Amgen, Inc., or Amgen, from 2003 to 2017, including Senior Vice President, Global Business Services from 2014 to 2017, Acting Chief Financial Officer in 2010 and 2014 and Vice President, Corporate Planning & Control and Chief Accounting Officer from 2005 to 2010. Prior to joining Amgen, Mr. Kelly previously served as Chief Financial Officer of Tanox, Inc. from 2000 to 2003 and as Vice President, Finance and Corporate Controller of Biogen, Inc. from 1998 to 2000 and Vice President, Finance and Chief Financial Officer of NutraSweet Kelco Company, a division of Monsanjto Life Sciences Company from 1996 to 1998. Our Board of Directors believes that Mr. Kelly's experience in the life sciences industry and his financial background qualify him to serve on our Board of Directors.
As the Independent Director of Hookipa Pharma Inc, the total compensation of Michael Kelly at Hookipa Pharma Inc is $227,506. There are 9 executives at Hookipa Pharma Inc getting paid more, with Joern Aldag having the highest compensation of $6,367,980.
Michael Kelly is 63, he's been the Independent Director of Hookipa Pharma Inc since 2019. There are 2 older and 15 younger executives at Hookipa Pharma Inc. The oldest executive at Hookipa Pharma Inc is Prof. Rolf M. Zinkernagel M.D., Ph.D., 77, who is the Co-Founder.
Michael's mailing address filed with the SEC is 9490 NEOGENOMICS WAY, , FORT MYERS, FL, 33912.
Over the last 21 years, insiders at Hookipa Pharma Inc have traded over $12,222,300 worth of Hookipa Pharma Inc stock and bought 1,455,824 units worth $18,573,557 . The most active insiders traders include Group, Llc Green Jeremy Red..., Bros. Advisors Lp Baker Bro..., and Deventer Sander Van. On average, Hookipa Pharma Inc executives and independent directors trade stock every 94 days with the average trade being worth of $180,581. The most recent stock trade was executed by Reinhard Kandera on 21 August 2023, trading 7,000 units of HOOK stock currently worth $5,110.
hookipa pharma inc. is a clinical stage company developing products to prevent and cure infectious diseases and cancer. with this goal in mind we created unique and cutting-edge technologies which reprogram and stimulate the immune system. our arenavirus technologies, vaxwave®, a replication-deficient viral vector, and therat®, an attenuated replicating vector, induce potent pathogen-neutralizing antibodies and cd8+ t cells. both, vaxwave® and therat®, can be administered repeatedly while maintaining their efficacy. therat® induced cd8+ t cell responses to tumor antigens reach frequencies and potencies matching or exceeding those observed after adoptive t cell therapy. hookipa’s “off-the shelf” viral vectors are administered systemically. they target dendritic cells in vivo and activate the immune system. in immune-oncology, this mechanism enables to fight solid tumors systemically, both primary and secondary (metastatic). at hookipa we have successfully completed a phase 1 trial of a
Hookipa Pharma Inc executives and other stock owners filed with the SEC include: